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Despite the fact that the database documenting amphetamine-related effects in humans 
has increased over the past decade, there remain important gaps in our knowledge of the effects 
of these drugs in humans. The current investigations, which examined the acute, repeated-dose 
and residual effects of amphetamine derivatives on various psychological measures in humans, 
addressed two of these gaps.  The first was the lack of empirical evidence directly comparing d-
amphetamine and methamphetamine.  Study 1 was the first direct comparison of the regulatory 
focus effects of intranasal d-amphetamine and methamphetamine (12, 50 mg/70kg).  Results 
indicate that the drugs produced overlapping effects on most measures (e.g. increased 
“prevention” focus state and task engagement).  Under the low dose condition, only 
methamphetamine increased “prevention” focus.  Study 2 was a within-participant investigation 
on the impact of three 3,4-methylenedioxymethamphetamine (MDMA) administrations (12 and 
24 hours intervals) on physiological, subjective, and behavioral measures in experienced MDMA 
users.  Heart rate, blood pressure, oral temperature, subjective effects, psychomotor performance, 
and sleep were assessed repeatedly throughout the study. Acute administration of MDMA 
produced systematic increases in heart rate, blood pressure, and subjective effects, but oral 
temperature was unaltered. Following repeated drug administration, heart rate elevations were no 
longer statistically significant; blood pressure and subjective-effect ratings remained 
significantly increased, but such increases were diminished relative to acute drug effects.  
Measures of sleep were decreased only on the evening following two active MDMA 
administrations. Performance alterations were not observed nor were MDMA-related toxic 
effects. Overall, the data from both studies do not support either: 1) the conventional notion that 
d-amphetamine and methamphetamine produce markedly different effects in humans; or 2) the 
general perception that MDMA produces dangerous cardiovascular and subjective effects in 
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Chapter 1: General Introduction 
1.1 History of Amphetamines in the United States 
 
1.1.1 d-amphetamine and methamphetamine 
 
Synthesis of amphetamine 
 
Although certain amphetamines (e.g., d-amphetamine, methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA)) have attracted popular attention only over the past 
two decades, the use of these compounds dates back to the early 1900s.  Of these compounds, d-
amphetamine was the first synthesized in 1887 by German chemist, Lazar Edeleano (Anglin et 
al., 2000).  Before amphetamine could be produced an important scientific development had to 
occur:  the synthesis of ephedrine (the active ingredient in the herb ma huang, Ephedra sinica 
plant) in 1885 by Japanese chemist, G. Yamanashi (Chen & Schmidt, 1926) and the re-synthesis 
of the drug by Ku Kuei Chen and Carl Schmidt in 1923.  Before amphetamines were used in 
medicine, ephedrine was used (e.g., as a nasal decongestant). 
This early research laid the groundwork for the use of the drug in medicine.  Eli Lilly and 
Company launched the first large-scale production of ephedrine in 1926: the drug dominated the 
pharmaceutical market as a treatment for 1) anaphylactic shock in patients with cardiac 
disorders, 2) chronic hypotension (i.e., low blood pressure), a classic symptom of Addison’s 
disease, 3) congestion for the common cold, and 4) asthma. 
The success of ephedrine as a therapeutic in relieving symptoms caused by clinical illnesses 
increased the public’s confidence in the use of medications.  By the late 1920s, ephedrine supply 
was low and prices were high due to the reliance of Eli Lilly and Company on overseas 
production.  This situation helped to stimulate scientific investigations in search of alternative 





Gordon Alles, synthesized several compounds that were structurally similar to ephedrine, 
including phenylisopropylamine (e.g., later named “amphetamine”): amphetamine is the basic 
ephedrine structure without the side chain hydroxyl group.  As a graduate student, Alles worked 
with John Jay Abel, a well-known pharmacologist who had isolated the pancreatic hormone, 
insulin, in 1926 (Parascandola, 2010).   
Early scientific research on amphetamine 
In 1930, Alles and colleagues published the first study of amphetamine comparing its 
cardiovascular effects with related compounds in dogs.  The researchers found that a single 
intravenous administration of amphetamine (50 mg) produced increases in blood pressure that 
persisted longer than other compounds.  It is important to note that only one dose level of 
amphetamine and related compounds was assessed and as a result, the dose-response curve is 
unclear: it is possible that the related compounds could have produced more robust effects than 
amphetamine at different doses.  
To enhance the translational relevance of the above study, Alles et al. (1930) conducted a 
subsequent study during which oral and subcutaneous doses (50 mg, 1 cc of 5% solution) of 
amphetamine and related compounds were compared in humans.  They observed that both oral 
and subcutaneous amphetamine produced marked increases in blood pressure and decreases in 
mouth and nose secretions.  These effects lasted 8 hours.  The comparator compounds failed to 
produce effects on any measure.  The researchers indicated amphetamine as an effective 
alternative medication to ephedrine for a wide range of clinical conditions (i.e., congestion from 
the common cold, asthma, hypotension). 
Being cognizant of pharmacokinetics, the researchers were also interested in comparing the 





subcutaneous administration of the drug produced identical effects.  However, the rate of onset 
of these effects was different between the two routes. When the drugs were taken orally, peak 
effects occurred about two and a half hours after ingestion.  In contrast, subcutaneous peak 
effects occurred approximately one and a half hours after administration, one hour before the 
onset of effects following oral dosing (Figure 1.1).  These findings were important because they 
led to the manufacturing of the drug in two forms (e.g., pill, injection), each providing patients 
with different advantages (i.e. convenience vs. rapid effects, respectively). 
In 1932, Alles gained sole patent rights to both amphetamine sulfate (pill) and amphetamine 
hydrochloride (injectable solution).  Shortly after, in 1933, Smith, Kline and French chemist, 
Fred Nabenhauer, developed and patented a slightly different preparation of the volatile free base 
form of amphetamine (e.g., a smokable form of the drug). This drug delivery method expanded 
the variety of clinical uses of amphetamine (i.e., as a nasal decongestant). That same year, Smith, 
Kline and French marketed the drug as an over-the-counter remedy for congestion and asthma 
(e.g., “Benzedrine” Inhaler) (Jackson, 1971) (Figure 1.2).  After negotiations with Alles, the 
pharmaceutical company also patented and manufactured “Benzedrine Sulfate,” the pill form of 
the Benzedrine inhaler, in 1934. Amphetamine became one of most versatile medications 
available on the market at this time. 
In order to best promote their new product directly to doctors, Smith, Kline and French 
placed advertisements in top medical journals (e.g., Journal of the American Medical 
Association, JAMA).  However, before gaining access to commercial space in medical journals, 
pharmaceutical companies were first required to receive the “Seal of Approval” of the American 
Medical Association’s (AMA) Council on Pharmacy and Chemistry. Under this policy, 





advantage” (Kremers & Sonnedecker, 1976).  This early requirement spurred a tremendous 
amount of research on amphetamine, and the findings and interpretations gave the impression 
that amphetamine was a panacea. 
In 1935, Smith, Kline and French funded several clinical investigations of amphetamine 
(Rasmussen, 2006, 2008).  The first of these studies was a clinical trial comparing the 
effectiveness of amphetamine and ephedrine to treat narcolepsy (Prinzmetal and Bloomberg, 
1935).  The researchers found that oral amphetamine (10-90 mg) reduced unexpected, abrupt 
onset of sleep  (e.g., a hallmark symptom of narcolepsy) in all patients.  This therapeutic effect 
was shown to last for up to 14 months, suggesting a lack of tolerance to amphetamine-related 
effects.  Prinzmetal and Bloomberg also found that ephedrine improved alertness in only 30% of 
patients and this effect diminished after one month, leading them to conclude that amphetamine 
was more effective than ephedrine as a narcoleptic medication. It’s important to note that this 
study was not double-blind or placebo-controlled, but at the time it was rigorous enough to be 
published in the top medical journal of this era, JAMA. 
Over the next few years, findings from several other clinical studies on amphetamine-related 
effects were published in scientific literature, increasing the avenues for which amphetamines 
could be prescribed. Several investigators assessed the ability of amphetamine to enhance mood 
in depressed individuals (Myerson, 1936; Guttman, 1936; Guttman & Sargant, 1937; Bloomberg, 
1939).  In a seminal, open-label study, Wilbur et al. (1937) administered low oral doses (2.5 - 20 
mg) of amphetamine once or twice daily for up to 6 months and found that amphetamine 
markedly enhanced mood in patients who suffered from mild to moderate depression, but not in 
patients diagnosed with severe depression.  Amphetamine effectiveness appeared to diminish 





findings are intriguing for multiple reasons. First, data from a recent study indicate a different 
pattern of effects: the benefit of antidepressant medications (all of which are FDA-approved and 
non-amphetamine-based) increases with the severity of depressive symptoms. That is, patients 
with severe depression benefit, while those with mild or moderate symptoms do not (Fournier et 
al. 2010).  Second, this early research contributed to current conventional wisdom that 
amphetamine loses its effectiveness as an antidepressant therapeutic largely. It is unclear whether 
amphetamine-related effects on depressive symptoms diminished in the majority of patients in 
that study. There are some psychiatrists who continue to use low doses of amphetamine (5-20 
mg/d) as an adjunctive treatment for depression, including members of the Depression 
Evaluation Services at the New York State Psychiatric Institute (communication with Dr. Jon 
Stewart). 
Another illness for which amphetamine was thought to be a potential clinical intervention 
was postencephalitic Parkinsonism. Parkinson’s disease is characterized by sleep and movement 
disruptions (i.e., REM sleep disturbances, daytime drowsiness, muscular rigidity).  Davis and 
Stewart (1938) investigated the effects of oral amphetamine (ranging from 40 – 60 mg, given in 
divided doses) using an open-label design.  The researchers found that amphetamine reduced 
symptoms of fatigue, muscular rigidity, and tremors in 72% of the patients. These findings were 
interpreted as extremely promising because the only other treatments were for Parkinsonism 
were choline-based drugs such as atropine and scopolamine, which appeared to be considerably 
less effective than amphetamine.    
Together, above data provided the necessary evidence for Smith, Kline and French to receive 
approval by the AMA Council to advertise “Benzedrine Sulfate” tablets for the treatment of 





and Chemistry, 1937) (Figure 1.3).  Amphetamine gained an increasing reputation as a panacea.  
This is consistent with the notion that began in the early 1900s that drugs were viewed as 
pharmacological tools to solve several health problems. Like insulin and penicillin, amphetamine 
was a newly minted member of a generation of breakthrough medications. 
Amphetamines and the military (World War II [1939-1945]) 
During World War II, the German military introduced a novel type of military warfare 
consisting of speed and surprise tactics (i.e., “Blitzkrieg,” “lightning war”), which often resulted 
in overworked, sleep-deprived soldiers.  German forces utilized drugs to solve such military 
problems.  In 1939, a new amphetamine-based drug, “Pervitin” (later named methamphetamine; 
in 3 mg tablets), was distributed to soldiers to offset battle fatigue, and enhance performance 
during demanding ground and air missions.  The drug closely resembles amphetamine in 
chemical structure and profile of effects: methamphetamine is the amphetamine structure with 
the addition of a methyl group and produces nearly identical effects as amphetamine (i.e., 
increases heart rate, blood pressure, alertness, euphoria) (Martin et al., 1971; Sevak et al., 2009; 
Kirkpatrick et al., 2011). It appears that the German military primarily used methamphetamine 
because of manufacturing limitations: amphetamine (Benzedrine) was predominantly 
manufactured in the U.S. 
Although methamphetamine was originally synthesized by Japanese scientist, Nagayoshi 
Nagai, in 1893 (and later synthesized by Akira Ogata, in 1919), it was not until 1938 that the 
Berlin-based Temmler pharmaceutical company marketed the drug to German doctors, namely 
military physicians (Grobler et al., 2011; Weisheit & White, 2009). Estimates indicate that 
approximately 35 million methamphetamine tablets were used by German forces between April 





Following their major defeat in 1940, British allied forces recognized the beneficial effects of 
amphetamines in war.  British media coverage was filled with accounts of “heavily drugged, 
fearless and berserk” German paratroopers who were largely credited at the time for the success 
of the 1940 mission (Rasmussen, 2008).  Shortly after their defeat, the Royal Air Force (RAF) 
commissioned experiments investigating the effects of various stimulants (i.e., amphetamine, 
methamphetamine and caffeine) on performance and mood in soldiers. In a series of field studies 
on long-range Coastal Command missions between 1941 and 1942, Winfield, a British medical 
officer, administered low, oral doses (up to 10 mg) of methamphetamine (e.g., “Methedrine”) 
and amphetamine (e.g., “Benzedrine”) to troops.  The researcher concluded that amphetamine 
and methamphetamine produced overlapping effects: both drugs increased alertness.  Because 
amphetamine was reportedly more effective at enhancing mood than methamphetamine, 
Winfield ultimately only recommended the use of amphetamine (5 mg) for long bomber flights.  
It is important to note that this study lacked double-blind conditions, allowing for the possibility 
of expectancy effects.  Nevertheless, the Royal Air Force heeded Winfield’s suggestion in 1942 
(Rasmussen, 2008). 
Aware of British research, the U.S. National Research Council (NRC) funded scientific 
amphetamine-related investigations in an effort to advise the U.S. Air Force on the possible 
benefits of pharmacological tools in war.  In the first of a series of decompression-chamber 
studies (e.g., under conditions of high altitude), Ivy and colleagues (1942) administered caffeine, 
amphetamine and methamphetamine alone and the combinations, caffeine and amphetamine, and 
amphetamine and methamphetamine, in normal and low pressure (e.g., altitudes up to 18,000 
feet) conditions. Again, the researchers found that amphetamine and methamphetamine produced 





performance compared to placebo (as cited in Rasmussen, 2011).  
Alongside this military research, the Illinois-based pharmaceutical company, Abbott 
Laboratories, funded studies investigating performance effects of amphetamines between 1941 
and 1942.  In one of these experiments, Ivy and colleagues administered intravenous caffeine 
(unknown dose), amphetamine (10-15 mg), methamphetamine (5 mg) and placebo to humans 
and found that caffeine and methamphetamine improved performance on strenuous physical 
fitness tests compared to amphetamine (Rasmussen, 2008).  These amphetamine-related effects 
are consistent with the fatigue-reducing effects of amphetamine in narcoleptic patients.  It is 
important to note, however, that the study included a design that varied both the dose and drug.  
It is unclear whether the drugs would produce similar effects at the same dose.  Regardless, in 
1942, Abbott expanded their product line and began marketing methamphetamine (“Desoxyn”) 
to physicians and the U.S. military (Weisheit & White, 2009). 
Despite empirical evidence indicating similarities between the two drugs, Ivy and colleagues 
ultimately only recommended amphetamine (Benzedrine in 5 mg tablets) for use by the U.S. Air 
Force in 1943 (Figure 1.4).  A major motivation for this decision was that amphetamine was 
viewed as a panacea for a number of ailments (i.e., fatigue, depression), some of which soldiers 
suffered.   Military psychiatrists and psychologists were increasingly concerned with U.S. troop 
“morale”: “shell shock” and “psychoneurotic breakdown” were thought to be on the rise in U.S. 
servicemen (Rasmussen, 2011).  Amphetamine was the only approved antidepressant at the time 
and researchers argued that, unlike methamphetamine, amphetamine increased performance 
primarily by enhancing mood.  In retrospect, this statement seems arbitrary in light of the fact 






Civilian use after World War II (1940-1950s) 
After the War in 1945, the medical use of amphetamine was expanded.  One new use was the 
treatment of “hyperkinetic” behavior in children (later known as Hyper-Attention Deficit 
Disorder (ADHD)).  In one of the first studies to show that the drug produced beneficial effects 
in this population, Bradley and Bowen (1940) examined the effects of single and repeated oral 
doses of amphetamine (10, 20, 30, and 40 mg) on the behavior of hyperkinetic children aged 5-
12 years.  They found that amphetamine enhanced attention and academic performance in more 
than 50 percent of the sample studied.  Around the same time, other researchers showed that the 
drug was an effective appetite suppressant (Rosenthal, 1940; Kunstadter, 1940).  By 1949, SKA 
had received approval from the AMA Council to market amphetamine as a treatment for 
depression, hyperkinetic behavior, and weight loss. As a result, SKA sales increased from $5.7 
million in 1947 to $7.3 million in 1949 (AMA, 1947; Jackson, 1976).    
Benzedrine advertisements increasingly included statements indicating the multiple 
therapeutic uses of amphetamine (i.e., for depression, unwanted weight gain): housewives were 
the main target of such ads because they were thought to suffer from a number of clinical 
conditions due to the “bor[dem] with the monotony of their unexciting lives” (Figure 1.5) 
(Rasmussen, 2006; Bett, 1946).  As can be seen in Table 1.1, by 1946, amphetamine was 
indicated for over 30 medical conditions (Bett, 1946) and was so versatile that it was even used 
as an analgesic (pain-reliever) in the White House by John F. Kennedy for his hurt back 
(Rasmussen, 2008).  
Amphetamines were also widely used for purposes other than medical. More people became 
aware of the multiple uses of amphetamines from scientific reports (Heal et al., 2013) and, 





pharmacies until 1959 (Anglin et al., 2000; Guttman & Sargent, 1937).  Truckers and students 
used amphetamines to offset sleep and extend hours beyond their normal sleep period (Tidy, 
1938; Heal et al., 2013).  Professional athletes, especially cyclists and baseball players, used the 
drugs to enhance alertness and counteract psychological decrements caused by fatigue.  
Amphetamines remain the drugs of choice in baseball, however, in 2006, they were finally 
banned and a prescription is now needed.  Furthermore, housewives and “Bohemian” groups 
(e.g., jazz, bebop, and beat subcultures) used the drugs to enhance their mood and sociability 
(Weisheit and White, 2009).    
Media Reports 
Over the course of only a few years, amphetamines shifted from panaceas to dangerous 
substances.  The many personal uses of amphetamines mirrored the variety of labels popular 
reports ascribed to the drugs in the 1940s and 1950s (e.g., “Pep-Pills,” “Confidence Drug[s],” 
and “New York’s Benzedrine Set”) (Jackson, 1971; Bett, 1946).  However, overtime, media 
coverage became increasingly filled with accounts of “supercharged” students cramming for 
exams and collapsing from substance use (Time, 1942, Science Newsletter, 1937). Several 
articles focused on the “harmful aftereffects” of the drugs on students’ “poisonous brain” (Time, 
1937, 1942). Media outlets initiated rumors over amphetamine-induced neurosis, even though 
the drugs were actually indicated to treat psychotic episodes (W.L.L, New York Times, 1947). In 
an article published in Time magazine, Benzedrine and Pervitin were stigmatized as “Nazi Pep-
Pills.” 
Scientific Reports: Long-term Effects of Amphetamines  
 In addition to negative media reports, there were statements in the scientific literature 





described unfavorable effects of long-term use of large amphetamine doses were hallucinations 
and paranoia (i.e., termed “amphetamine psychosis”) (Norman & Shea, 1945; Goodman & 
Gillman, 1941; Young & Scoville, 1938).  Such statements, however, were based on data from 
case studies conducted on an unrepresentative sample of the population (e.g., some participants 
had a history of depression, alcoholism etc.).  Other frequently reported deleterious effects 
associated with amphetamine abuse were malnutrition from appetite loss, xerostomia (dry 
mouth) and “burning of the gums” (Monroe and Drell, 1947).  But, it is important to consider the 
fact that these claims were based on behavioral observations from a field study and it is unclear 
if these phenomena had more to do with non-pharmacological factors, such as poor dental 
hygiene and nutrition, than pharmacological effects of amphetamines. 
At the time, data from scientific studies indicating no deleterious effects of long-term 
amphetamine use were largely ignored.  For example, Bakst (1944) conducted a case study on a 
user who had administered low to moderate doses (15-30 mg) of amphetamine daily for about 9 
years.  No untoward dental or psychological effects of the drug were observed.  Although this 
study shared similar limitations as aforementioned studies (e.g., lacked controlled, double-blind 
conditions), it provided important information to the growing database documenting the long-
term effects of amphetamine use in humans.   
Despite these mixed findings, members of the medical community became increasingly 
concerned about the unfavorable effects associated with amphetamine use.   JAMA headlined one 
article, “Benzedrine Sulfate—A Warning,” describing the toxic and addictive effects of long-
term use of the drug, urging doctors to limit prescriptions for medical conditions. By 1947, new 
regulations made amphetamine tablets (Benzedrine Sulfate) available by prescription only in 





should only be used under the close supervision of a physician (Jackson, 1971; Anglin, 2000; 
Monroe & Drell, 1947).   
Pharmaceutical Companies’ Response to Negative Reports 
Following warnings of the unpredictable and addictive effects of their product, 
Benzedrine Sulfate, Smith, Kline and French commissioned several studies investigating the 
safety and efficacy of a potential alternative amphetamine-based drug, dextro-amphetamine (e.g., 
“Dexedrine”).  The amphetamine molecule exists in two, asymmetric forms known as optical 
isomers (e.g., left-handed [levo-amphetamine] and right-handed [dextro-amphetamine] versions) 
(Figure 1.6) and in 1938, company chemists discovered a method of separating the two isomers, 
allowing for comparison studies of the effects of all three types of amphetamine.   
Alles, the chemist who previously synthesized and patented Benzedrine (e.g., a racemic 
mixture of equal parts dextro- and levo-amphetamine), and Prinzmetal, the first scientist to study 
the effects of amphetamine in narcoleptic patients, conducted a series of comparison studies on 
the effects of all three compounds. In the one of these studies, Alles and Prinzmetal (1940) 
administered oral doses of dextro-amphetamine (10-28 mg), levo-amphetamine (20-50 mg), and 
racemic amphetamine (Benzedrine; 20-50 mg) to patients diagnosed with narcolepsy or 
postencephalitic Parkinson’s disease.  They found that, in comparison to levo-amphetamine and 
racemic amphetamine, dextro-amphetamine produced greater decreases in 1) unexpected, abrupt 
onset of sleep in all narcoleptic patients, and 2) fatigue, muscular rigidity and tremors in 50% of 
patients diagnosed with postencephalitic Parkinson’s disease.  Furthermore, no negative effects 
of dextro-amphetamine were observed. It is important to note, however, that researchers 
compared different doses of each drug, making it difficult to decipher the real differences 





patented and marketed dextro-amphetamine (“Dexedrine”) as a safe and effective substitute 
medication for the treatment of narcolepsy and postencephalitic Parkinson’s disease.  
Amphetamine “Epidemic” in 1950s-1970s 
By the mid 1950s, national concerns about recreational amphetamine abuse were on the 
rise.  The New York Times headlined one story, “Ours is the Addicted Society” (Farber, 1966).  
One factor that contributed to this increased worry about “habit-forming” drugs was that 
intravenous (IV) administration, which is associated with more intense, potentially more 
deleterious drug-related effects, was becoming popular in drug subcultures (e.g., heroin users).  
When a drug is given by injection, it directly enters the bloodstream without going through the 
stomach, intestines, and liver.  In comparison to oral administration, IV administration produces 
a more rapid onset of effects because drugs access the brain faster.   This route is associated with 
a higher abuse potential in humans primarily because some researchers have argued that the 
more immediate drug-effects allow the drug to act as a more robust reinforcer.  This route of 
administration is also stigmatized because it is the preferred route of heroin users, who are 
commonly viewed as being “more committed” drug abusers.   
In the early 1960s, heroin and cocaine were often administered together using the 
intravenous route of administration (e.g., speedball) and IV users soon realized that similar drug 
effects could be produced by combining heroin and amphetamine.  Amphetamine gained the 
nickname, “speed” (most likely due to the rapid “high” produced by IV administration).   
Recreational users would extract the medicated wick inside the Benzedrine Inhaler, soak it in 
water or coffee, and inject the remaining solution (Jackson, 1975).  An injectable form of 
methamphetamine was also available by prescription for the treatment of heroin addiction 





Stories on this new, potentially more deleterious method of administering amphetamines 
started to appear in the national press.  For example, New York Times articles commented that 
this form of amphetamine “induces a strong, fast high” and an “intense feeling of power” 
(Kifner, 1967).  Popular press articles describing street corners of “speed freaks” were common 
(Golden, 1967), and by 1967, public service announcements from an anti-amphetamine 
campaign, whose slogan was “Speed Kills,” were familiar messages on radio stations 
(Rasmussen, 2008).  Warnings, such as “Methedrine Use is Growing,” also headlined articles 
from prominent newspapers (Kifner, 1967, Severo, 1971).  These statements in the popular press 
increased public concern about a supposed amphetamine “epidemic”  (Robinson, 1967; Black, 
1970).  
In 1970, growing public concern, in turn, motivated policy-makers to pass new legislation: 
Congress enacted the Comprehensive Drug Abuse Prevention and Control Act which created 
five “schedules” of controlled substances as a system to balance the potential medical uses of a 
substance with its abuse potential (Miller and Hughes, 1994).   Drugs are classified into one of 
five of these categories depending on the accepted medical use and abuse potential of the drug 
(Table 1.2).  For example, Schedule I drugs (e.g., Heroin, Marijuana, LSD) are considered to 
have no acceptable medical use and a high potential for abuse.  Drugs in this category are 
considered to have no acceptable medical use in treatment in the U.S., lack safety for use, have a 
high potential for abuse, and are not available by prescription. Drugs classified in Schedules II-V 
(e.g., morphine, cocaine, oxycodone) are considered to have an accepted medical use and a low 
to moderate potential for abuse, and are available by prescription. 
Under this policy, amphetamine and methamphetamine were placed under Schedule II.  Strict 





and recreational use of these drugs was made illegal in the U.S. (Miller and Hughes, 1994). 
Pharmaceutical amphetamines companies (e.g., Abbott and Burroughs Wellcome) withdrew their 
intravenous amphetamine products from the prescription marketplace, giving rise to synthesis of 
illicit recreational methamphetamine in clandestine underground laboratories (“meth labs”) 
(Miller, 1996) (Anglin et al., 2000).   
1.1.2 3,4-methylenedioxymethamphetamine 
3,4-methylenedioxymethamphetamine (MDMA) is similar in structure to amphetamine and 
methamphetamine: the drug is the basic methamphetamine with an additional methyldioxy ring.  
Recent research findings indicate that it produces a similar profile of effects as the two other 
stimulants (i.e., increased heart rate, stimulation, and euphoria) (Kirkpatrick et al., 2011).  
Although MDMA was initially discovered and patented in 1912 by Merck Scientists as an 
intermediate compound in the chemical synthesis of methylhydrastinine (e.g., a medication used 
to reduce bleeding), the drug received little further attention until 1953 (Bernschneider-Reif and 
Freudenmann, 2006). From 1953 to 1964, the Scientific Intelligence Division of the Central 
Intelligence Agency (CIA) in collaboration with the Special Operations Division of the Army’s 
Chemical Corps launched the classified MK-ULTRA experimental program which consisted of a 
series of studies investigating different methods of “manipulating human behavior” (Michale-
Robinet, 1994).  MDMA was included as one of several psychoactive drugs (i.e., LSD, 
psilocybin, heroin) tested as potential tools for espionage (e.g., “brainwashing,” polygraph 
testing) in these confidential studies. The CIA primarily focused on MDMA most likely because 
of two effects that were thought to be divergent from amphetamine and methamphetamine: 





body, alterations of auditory and visual input) and empathogenic properties (i.e., increased 
openness and communication, “truth serum”).  
In general, Army researchers recruited individuals from U.S. universities, prisons and 
hospitals and surreptitiously administered these drugs to subjects.  Although some reports from 
the project were declassified in 1994, details regarding the results of these experiments are 
limited. The program was eventually curtailed in the early 1960s following an accidental death 
of a subject due to overdose and was officially terminated in 1973 (Karch, 2011).  It is important 
to note, however, that previous research found no evidence of MDMA-related cardiovascular 
toxicity in animals (e.g., rats, mice, monkeys) (Hardman et al., 1973). 
Around the time of the program conclusion, Alexander Shulgin, a U.S. chemist, was growing 
increasingly interested in the effects of mescaline analogs (e.g., MDA, MMDA) and in 1965, re-
synthesized MDMA (Karch, 2011).   In the first published article on the effects of MDMA in 
humans, Shulgin and Nichols (1978) reported that moderate to high, oral doses (75-150 mg) of 
MDMA produced perceptual alterations (e.g., “an altered state of consciousness with emotional 
and sensual overtones”) in humans.  The researchers also noted that the drug produced limited 
physiological residual effects. 
Despite the fact that there was minimal evidence on the psychological effects of the drug in 
humans, Shulgin reportedly suggested the use of MDMA as a therapeutic aide to the psychiatric 
community.  Due to its purported ability to increase openness and empathy in humans, the drug 
became popular among medical professionals (e.g., psychiatrists, psychotherapists) as well as the 
general public (Benzenhofer & Passie, 2010).  A distribution group in Texas (e.g., “The Texas 





credit card over the phone by calling a toll-free number and at nightclubs in Dallas and Fort 
Worth, Texas (Holland, 2001).   
Texas Senator and Member of the Senate Judiciary Committee, Lloyd Bentsen, grew 
concerned over this new recreational use pattern of MDMA in his state and in 1984, submitted a 
request to the Drug Enforcement Administration (DEA) to “emergency” schedule MDMA.  
Under this policy, the Justice Department was permitted to immediately place a drug on a 
Schedule without a congressional hearing and in 1985, MDMA was placed on Schedule I, where 
it remains today.  
2.1 Concluding Thoughts 
 Despite the tremendous amount of early research indicating that amphetamines can be 
used safely within a therapeutic dose range, sensationalized media portrayals of the drugs 
trumped scientific findings.  Accordingly, public concerns and policies related to amphetamines 
were ultimately shaped by anecdotal reports. There was, however, no real evidence supporting 
popular claims about amphetamine-associated toxicity. Despite the growing scientific database 
documenting the effects of amphetamines in humans, there are still considerable gaps in our 
knowledge. The following studies were conducted to address these gaps and dispel some of the 
















Chapter 2: The Effects of Intranasal d-Amphetamine and Methamphetamine on Regulatory 
Focus Measures in Humans 
 
2.1 Introduction 
Following decades of dormancy, the abuse of amphetamines has again become an 
important public health issue globally.  Methamphetamine, in particular, has generated the 
greatest amount of concern because it is considered to have a higher abuse potential relative to 
other amphetamines (e.g., d-amphetamine, the active ingredient in “Adderall”).  The U.S. 
Treatment Episode Data Set (TEDS) system enumerates substance abuse treatment episodes 
across the Nation.  According to this Data Set, in 2011, approximately 102,00 treatment-seeking 
individuals aged 12 years or older reported methamphetamine as their primary substance of use, 
while about only 8,000 users seeking treatment reported d-amphetamine as a principal drug of 
abuse (TEDS, 2013). Furthermore, the Drug Abuse Warning Network (DAWN) provides data on 
drug-related emergency room visits from major metropolitan areas (e.g., number of visits 
associated with a particular drug or drug combination). In 2011, d-amphetamine-related 
emergency department episodes were also low in comparison to methamphetamine-related 
episodes (e.g., ~17,000 vs. ~102,000 episodes, respectively) (DAWN, 2011). An important 
consideration, however, is that these abuse rates may be related to the fact that methamphetamine 
is apparently easier to synthesize than d-amphetamine, making it a more readily accessible drug 
on the illicit market. 
Another explanation for the greater incidence of methamphetamine abuse has to do with the 
slight structural difference between the two drugs: methamphetamine is the N-methylated analog 
of d-amphetamine.  Some researchers argue that the additional N-methyl group (CH3) in the 
methamphetamine structure increases the lipid solubility of the compound, perhaps allowing it to 





(e.g., Gulaboski et al., 2007; Nichols, 1994, de Wit et al., 1993).  Consequently, 
methamphetamine is considered to be a more robust reinforcer, which is expected to lead to a 
higher abuse liability.  
This notion, however, is inconsistent with empirical data from research collected in animals 
(Hall et al., 2008; Yokel and Pickens, 1973) and humans (Lamb and Henningfield, 1994; Sevak 
et al., 2009, Kirkpatrick et al., 2011).  For example, data from behavioral studies conducted in 
rats indicate that d-amphetamine and methamphetamine similarly increase locomotor activity 
and self-administration at equipotent doses (Hall et al., 2008; Balster and Schuster, 1973; Yokel 
and Pickens, 1973).  Furthermore, in one double-blind study, Martin et al. (1971) administered 
subcutaneous doses of d-amphetamine (7.5-30 mg/kg) and methamphetamine (15-30 mg/kg) in 
humans and found that both drugs similarly increased cardiovascular activity and ratings of 
euphoria in comparison to placebo.  In general, these data are consistent with other reports 
indicating that oral doses of d-amphetamine (2.5-45 mg) and methamphetamine (2.5-30 mg) 
produce overlapping mood and reinforcing effects (Lamb and Henningfield, 1994; Sevak et al., 
2009).  
It is important to note, however, that these investigations compared oral and subcutaneous 
amphetamines at doses lower than those typically used by abusers of the drugs. Abusers also 
tend to use drugs via routes that are associated with rapid onset of effects such as intranasal, 
intravenous injection, and smoked.  For example, illicit methamphetamine is reportedly used in 
larger doses (e.g., greater than 25 mg) via the intranasal, intravenous, and smoked routes of 
administration, presumably due to their faster onset of effects (Simon et al., 2002).  As a result, 






Another reason for concerns surrounding methamphetamine abuse might be related to the 
database collected in laboratory animals on methamphetamine-related neurotoxic effects.   In 
general, data from these studies indicate that methamphetamine produces deleterious 
neurochemical consequences.  For example, Ricaurte and colleagues (1980) administered large, 
subcutaneous doses of methamphetamine (25 and 100 mg/kg) for 4 consecutive days to rats. 
They found that methamphetamine produced significant decreases in dopamine and serotonin 
levels in several brain regions (i.e., striatum, amygdala) 3-6 weeks following drug-
administration.  The researchers concluded that methamphetamine produced long-term 
neurotoxicity to dopamine and serotonin neurons.  It is important to note, however, that the doses 
administered in this study far exceeded those typically used by recreational humans users.  For 
example, recreational methamphetamine users usually take approximately 0.25-3.5 mg/kg (Cho 
et al., 2001).  In addition, Hart et al. (2012) recently published a critical review of findings from 
neuroimaging research investigating the acute and long-term cognitive and neurotoxic effects of 
methamphetamine.  The researchers reported that the majority of theses studies included 
inappropriate controls and limited cognitive testing and concluded that the findings were largely 
overstated.  As a result, the above results provide limited information about the consequences of 
methamphetamine use in humans. 
In an effort to address the limitations of previous research, the current experiment was 
conducted as part of a larger investigation comparing the effects of amphetamines (Kirkpatrick et 
al., 2011).  Kirkpatrick and colleagues administered relatively large, intranasal doses of d-
amphetamine (12 and 50 mg/70kg), methamphetamine (12 and 50 mg/70kg), and placebo to 
current methamphetamine users over the course of five 2-day blocks of sessions. On the first day 





monetary reinforcer (U.S. $5 or $20). On the following day (the “choice” session), participants 
were given the opportunity to choose between the sampled drug and/or money.  They found that 
the drugs produced similar reinforcing effects: when the competing monetary reinforcer was 
relatively low (i.e., $5), d-amphetamine and methamphetamine similarly increased drug self-
administration.  It is important to note, however, that this larger investigation primarily examined 
drug-related effects on self-administration using a standard choice procedure.  Although these 
measures provide potentially useful information about the similar abuse liability of 
amphetamines, it is possible that only more sensitive subjective measures are able to detect 
potential differences between d-amphetamine and methamphetamine.   
Current research in the field of social psychology may provide useful tools for identifying 
possible discrepant effects of amphetamines.  For example, investigations on regulatory focus 
theory (Higgins 1997, 1998) indicate that individuals can temporarily experience motivational 
states of “promotion” focus (e.g., focus on hopes and accomplishments [gains]) and/or 
“prevention” focus (e.g., focus on safety and responsibility [nonlosses]) (Higgins et al., 2001). 
Other investigations indicate that when these motivational orientations (e.g., “promotion” focus 
and “prevention” focus) are sustained by preferred strategies of goal pursuit (“eager” for 
promotion focus and “vigilant” for prevention focus), individuals experience a regulatory “fit” 
that strengthens their engagement in a task (Higgins, 2000, 2005).  It is important to note that 
human behavioral pharmacology labs often measure performance on psychomotor tasks, some of 
which (i.e., Divided Attention Task [DAT]) require “vigilance” (prevention), while others (e.g., 
Digit Substitution Task [DSST]) require “eagerness” (promotion).  It is possible that the 
amphetamines might produce differential effects on these more nuanced subjective measures of 





The present investigation was conducted in an effort to understand further the comparative 
effects of d-amphetamine and methamphetamine on well-validated measures that are designed to 
assess more sensitive behavioral measures, such as regulatory focus and regulatory engagement 
effects (e.g., Regulatory Focus Questionnaire [RFQ], etc.).  Single, intranasal doses of 
methamphetamine and d-amphetamine (0, 12, 50mg/70kg each) were administered in current 
methamphetamine users. We hypothesized that: 1) d-amphetamine and methamphetamine would 
dose-dependently increase “prevention” focus because previous data indicated that intranasal 
methamphetamine improved performance on tasks of “vigilance” (e.g., DAT) and produced no 
significant performance effects on tasks relating to promotion system (e.g., DSST) (Hart et al., 
2008), and 2) d-amphetamine and methamphetamine would dose-dependently increase 
engagement ratings on a task involving the use of “vigilant” strategies (DAT), suggesting a 
possible “regulatory fit” with the prevention system. Because methamphetamine produced 
greater increases in various subjective ratings compared to d-amphetamine (e.g., “high”) in the 
larger behavioral study (Kirkpatrick et al., 2011), we further predicted that methamphetamine 
would dose-dependently produce greater increases in subjective ratings of “prevention” focus 
and “task engagement” in comparison to d-amphetamine. 
2.2 Methods and Materials 
2.2.1 Participants 
Thirteen male research volunteers completed this 10-session outpatient study (mean age 
= 37.4 ± 7.3 [mean ± standard deviation (SD)]): one was Asian, six were Black, two Hispanic, 
and four were White.  Participants had completed 14.8 ± 2.0 (mean ± SD) years of formal 
education. All participants were solicited via word-of-mouth referral, and various online and 





consent form that was approved by the Institutional Review Board of the New York State 
Psychiatric Institute (NYSPI); each passed comprehensive medical and psychiatric evaluations 
and were in within normal weight ranges according to the 1983 Metropolitan Life Insurance 
Company height/weight table (body mass index: 24.9 ± 2.7 [mean ± SD]).  Three participants 
met criteria for current methamphetamine dependence.  All participants stated that they were not 
seeking treatment for his drug use and no one met criteria for any other Axis I disorders.  On 
average, participants reported using methamphetamine 9.4 ± 4.7 days/month.  Seven reported 
current alcohol use (4-10 drinks/week), seven reported current cocaine use (1-8 days/month), 
three reported current marijuana use (4-12 days/month), and four smoked three to 20 tobacco 
cigarettes per day. 
2.2.2 Pre-study training 
Prior to starting the study, participants completed two training sessions (3-4 hours per 
session) on computerized psychomotor tasks that would be used in the study in order to 
minimize the effects of learning on task performance.  On a separate day, participants received 
the largest single dose of methamphetamine (50 mg/70kg) to be tested in order to monitor any 
adverse reactions and provide them with experience with the study drug in the laboratory setting. 
No adverse cardiovascular effects were noted. Participants were not informed of the dose until 
study debriefing.  
2.2.3 Design 
This within-participants study examined two intranasal methamphetamine and two 
amphetamine doses (12, 50 mg/70kg each drug) and placebo over the course of two weeks. 
Table 1 shows that the study consisted of five 1-day blocks of sessions during which one drug 





and psychomotor effects of methamphetamine and d-amphetamine. For the purposes of this 
paper, such effects will not be discussed (Kirkpatrick et al., 2011).  
2.2.4 Procedure 
All laboratory sessions began at approximately 0900 hours and lasted for 6 hours. 
Following a light breakfast, volunteers were required to pass a field sobriety test and give a urine 
sample that tested negative for several drug metabolites (excluding amphetamines and THC).  
They also completed a baseline psychomotor battery (see below).  After baseline assessments, 
participants insufflated the drug.  All study measures were assessed 30 minutes post drug 
administration. Upon study completion, participants were evaluated for signs of intoxication and 
required to pass a field sobriety test after which they were excused and given compensation for 
public transportation. 
2.2.5 Psychomotor Task 
 The computerized 10-min Divided Attention Task consisted of simultaneous pursuit-
tracking and “vigilance” tasks (DAT; Miller et al., 1988).  In this task, participants were required 
to track a moving circle on the video screen using the mouse, and also signal when a small black 
square appeared at any of the four corners of the screen. Accurate tracking of the moving 
stimulus increased its speed proportionately.  Data from the previous, larger study have already 
been published (Kirkpatrick et al., 2011). 
2.2.6 Regulatory Focus Questionnaire (RFQ) 
 The 11-item Regulatory Focus Questionnaire (RFQ; Higgins et al., 2001) consisted of a 
series of 5-point lines labeled “never or seldom” at one end and “very often” at the other end.  
Participants were required to rate their subjective histories of “promotion” and “prevention” 





life”; prevention success: “Not being careful enough has gotten me into trouble at times 
(reversed scored)”).  This measure is designed to assess subjective experiences of being effective 
in each motivational system.  A higher score on the promotion items reflects the “promotion 
system working,” or a subjective history of effectiveness with promotion-related “eagerness” 
(i.e., being bold and optimistic; being willing to take chances).  A higher score on “prevention” 
pride reflects the "prevention system working," or a subjective history of effectiveness with 
“prevention”-related “vigilance” (i.e., being careful and accurate; avoiding mistakes).  
2.2.7 State Regulatory Focus Questionnaire 
The 3-item State Regulatory Focus Questionnaire (see Zhou and Pham, 2004) consisted 
of a series of 9-point lines labeled with two consumer options (option A and B), one relating to 
the promotion system (e.g., a product emphasizing advancement and achievement) and the other 
relating to the “prevention” system (e.g., a product emphasizing safety and security) at each end.   
Participants were required to indicate their preference using a 9-point scale: 1= option A and 9= 
option B.  Higher numbers indicate a higher preference for “prevention”-related strategies (e.g., 
being “vigilant”). 
2.2.8 Task Engagement Questionnaire 
The 11-item engagement strength questionnaire consisted of a series of 9-point lines 
labeled “disagree strongly” at one end, “neutral” in the middle, and “agree strongly” at the other 
end (Higgins, 2006).  Immediately after the end of the DAT task, participants were required to 
rate the extent to which they felt engaged in the task (e.g., “I was completely focused on the 
task”) and their mood during the task (e.g., “I felt good during the task”).  Participants were also 
asked to rate “motivation to take the drug again” on a 9-point scale: 0= “not at all motivated,” 4= 






 The New York State Psychiatric Institute (NYSPI) Pharmacy provided methamphetamine 
HCL [provided by the National Institute on Drug Addiction (NIDA)] and d-amphetamine sulfate 
(provided by Cambrex, Charles City, IA, USA). Placebo consisted of powder containing only 
lactose and was added to each active amphetamine dose (12 and 50 mg/70 kg) to achieve a final 
weight of 60 mg/70 kg.  A research nurse placed each dose in a small medicine cup along with a 
straw.  Participants were required to insufflate the full dose within a 30 second period in either 
one or both nostrils.  All drug doses were administered  
2.2.10 Data Analysis 
Repeated-measures analyses of variance (ANOVA) with planned comparisons were used 
to determine the effects of d-amphetamine and methamphetamine on subjective ratings of 
regulatory focus state and task engagement. The dependent measures were analyzed using a two-
factor repeated-measures ANOVA: the first factor was dose (0, 12, and 50 mg/70 kg), and the 
second factor was drug condition (methamphetamine and d-amphetamine). For all analyses, 
ANOVAs provided the error terms needed to calculate planned comparisons that were designed 
to determine the effects of drug (methamphetamine vs d-amphetamine) and dose level (e.g., 0 mg 
vs two active methamphetamine doses and 12 mg vs 50 mg methamphetamine dose). Data were 
considered statistically significant at p < 0.05, using Huynh–Feldt corrections where appropriate. 
2.3 Results 
2.3.1 Regulatory Focus Questionnaire (RFQ) 
Figure 2.1 shows the effects of dosing condition on participants’ responses to the 





methamphetamine dose increased participants’ subjective ratings of their “prevention” focus (p < 
.05). No other regulatory focus effects were observed.  
2.3.2 State Regulatory Focus Questionnaire 
Figure 2.2 shows the effects of dosing condition on state regulatory focus ratings.  
Compared to placebo, both large doses of amphetamines and the 12-mg dose of 
methamphetamine increased self-reported preference for “prevention” focus strategies (p < .05).  
No other significant drug effects on state regulatory focus were noted.  
2.3.3 Task Engagement Questionnaire 
Figure 2.3 shows the effects of dosing condition on selected task engagement ratings.  
Relative to placebo, all active doses of amphetamines significantly increased ratings “completely 
focused on the task,” and “felt involved during task,”  (p < .05).  Both large doses and the 12-mg 
dose of methamphetamine significantly increased ratings of “motivated to get same drug dose” 
compared to placebo (p < .05). Table 2.1 summarizes other significant effects observed on the 
task engagement questionnaire. 
2.4 Discussion 
 As predicted, the current findings indicate that both large doses of the drugs enhanced 
ratings of “prevention” focus on both the state and chronic effectiveness measures of regulatory 
focus. That is, both drugs enhanced participants’ preferences for “reliable” (over “luxurious”) 
consumer options and effectiveness in being “vigilant.”  Consistent with these results, d-
amphetamine and methamphetamine produced similar effects on task engagement: both drugs 
increased ratings of “involvement” and “focus” during the task in all active dose conditions.  In 
general, these results are consistent with previous studies showing that d-amphetamine and 





Kirkpatrick et al., 2011). The current study extends earlier findings by providing the first data 
directly comparing the regulatory focus effects of the two drugs in humans.  These findings are 
important because they expand the limited database documenting the social psychological effects 
of amphetamines on motivational states. 
The overall pattern of d-amphetamine- and methamphetamine-related effects suggests 
that participants experienced a similar regulatory “fit” between their temporary motivational 
state (e.g., “prevention” focus) and the psychomotor task designed to measure “vigilance” (e.g., 
DAT).  Regulatory “fit” is experienced when an individual’s temporary motivational orientation 
(e.g. “prevention”) is sustained by a task that requires the use of preferred strategies (e.g., 
“vigilant” strategies), and results in greater levels of engagement and enjoyment during a task. In 
the current study, participants reported higher levels of engagement on the psychomotor task 
under all active drug conditions (e.g, under high “prevention” focus conditions) relative to 
placebo.  This comment is speculative, however, and suggests avenues for further investigation.  
For example, future research should include 1) a regulatory “nonfit” condition, which would 
consist of a task, such as the Rapid Information Task (RIT), that requires the use of “eager” 
strategies (i.e., making “hits”), and 2) additional measures that are designed to assess 
characteristic emotions associated with regulatory “fit” (e.g., feeling “right,” “effective”).  
We hypothesized that methamphetamine would produce greater increases in ratings of 
regulatory focus and task engagement compared to d-amphetamine. This prediction was not 
borne out.  The drugs produced equipotent motivational effects.  This prediction was based, in 
part, on the previously published behavioral study indicating that methamphetamine produced a 
more prominent effect on a subjective measure (e.g., in ratings of “high”) compared to d-





(2011) observed that d-amphetamine and methamphetamine produced nearly identical effects on 
the majority of subjective measures.  In general, the current observations are consistent with 
these data from the previous study.  
However, one potential explanation for the inconsistency with results from Kirkpatrick et 
al. (2011) indicating that methamphetamine produces greater subjective effects (e.g., on ratings 
of “high”) is that the previous investigation used a measure (e.g., Visual Analogue Scale [VAS]) 
that is designed to assess different, more general psychological concepts than those tested in the 
current experiment (i.e., subjective mood, drug effects, and physical symptoms).  The current 
measures are designed to investigate temporary motivational states and involvement in a task 
(e.g., of “eagerness” and “vigilance”) and allow for unique predications about distinct types of 
desired end-states and “pleasure” (euphoria).  It is possible that measures designed to assess 
specific “prevention”—related behavioral tendencies (e.g., conservative bias in decision-making, 
preference for stability over change, and concrete ways of thinking etc.) and other motivational 
states (e.g., Regulatory Mode) would be more effective in differentiating between the two drugs.   
Another potential explanation for the apparent incongruence between the present data and 
previous results is related to different data collection/analysis methods.  The current study 
assessed amphetamine-related subjective effects at one time point (e.g., 30 minutes), whereas the 
previous study included a wide range of time points and subjective-effect ratings data were 
summed across these time points.  It is unclear whether divergent regulatory focus and 
engagement effects of the drugs would emerge at other points along the time course.  Future 
studies on amphetamine-related regulatory focus effects should include multiple data collection 





It is intriguing that methamphetamine enhanced ratings on “prevention” focus and certain 
engagement measures (e.g., “motivated to get same drug dose,” “felt good during task”) in the 
low dose condition (12 mg) while d-amphetamine did not. It is important to note, however, that 
there was a nonsignificant trend in the data indicating that the smaller amphetamine dose 
increased “prevention focus” (p = .08).  These data suggest a subtle quantitative difference 
between both drugs and highlight the importance of considering dose potency when comparing 
drug effects: it is possible that d-amphetamine would produce similar qualitative effects 
compared to a 12-mg dose of methamphetamine at slightly higher doses (e.g., 20-30 mg).  Future 
research investigating the motivational effects of amphetamines should include a wider range of 
doses. 
In general, these results support our predictions.  The present findings show that 
relatively large intranasal doses of d-amphetamine and methamphetamine produce nearly 
identical effects on regulatory focus and task engagement measures: both drugs increased ratings 
of “prevention” focus and engagement in a task that was designed to assess “vigilance” and 
inhibitory control.  While the current data lend support to the idea that similar regulatory “fit” 
experiences were produced between both d-amphetamine- and methamphetamine-related states 
of “prevention” and the psychomotor task, future research is necessary.  Another important 
finding was that only methamphetamine produced self-reported increases in prevention focus 
under the low dose condition (12-mg dose). This result highlights the importance of assessing 
more sensitive self-report measures (e.g., regulatory focus) at a wider range of doses when 








Chapter 3: Acute, Repeated-dose and Residual Effects of 3,4-methylenedioxymethamphetamine 
MDMA in Humans 
 
3.1 Introduction 
Recreationally, 3,4-methylenedioxymethamphetamine (MDMA) is a popular 
amphetamine that has attracted considerable attention in recent years. According to the United 
Nations Office on Drugs and Crime (UNODC), amphetamine-type stimulants (ATS), which 
include MDMA, are the second most-widely used drugs globally, only exceeded by cannabis use 
(UNODC, 2012). Because multiple drugs are included in the ATS grouping - including 
methamphetamine, d-amphetamine, and MDMA – it is difficult to distinguish the extent of 
MDMA use from that of other drugs in this category. In United States, however, MDMA is 
differentiated from other ATS on surveys of drug use. The U.S. National Survey on Drug Use 
and Health, for example, provides estimates of individual drug use by people aged 12 years or 
older. When asked about illicit drug use within the past 30 days (or past year), respondents 
reported greater amounts of MDMA use than other substances including methamphetamine and 
crack cocaine (SAMSHA, 2011). Together, these findings indicate that recreational MDMA use 
is substantial. 
MDMA is used in a variety of social settings, including at night and on weekends. During 
this time, multiple doses may be taken within a 48-hour period, which could lead to dangerous 
additive effects, residual effects and impact next-day functioning. Indeed, in the U.S., there have 
been at least two recent deaths attributed to repeated-dosing effects on MDMA (also known as 
Molly) (Pareles, 2013). In addition, some anecdotal reports suggest that MDMA users may 
experience negative mood states (e.g., "Lethargic," "Depressed") in the days immediately 





The available data from laboratory investigations of the drug in humans have focused 
almost exclusively on the acute effects of MDMA following single-dose administrations (e.g., 
Cami et al. 2000; Kuypers & Ramaekers, 2005, 2007; Tancer & Johanson 2001). In general, 
MDMA, at doses ranging from ~75 to 145 mg, produces effects similar to those produced by d-
amphetamine and methamphetamine: increases in positive subjective effects, blood pressure, and 
heart rate (Bedi et al., 2010; Cami et al. 2000; Harris et al. 2002; Tancer & Johanson, 2003, 
2007).  Unlike the amphetamines mentioned above, MDMA has also been shown to either 
disrupt performance (e.g., Cami et al. 2000) or produce no performance alterations (e.g., 
Marrone et al. 2010; Kirkpatrick et al., 2012). These data, however, do not provide information 
about next-day consequences of MDMA use; nor do they provide any information about 
repeated-dose administration.  
Only a few laboratory studies have assessed amphetamine-related effects following 
repeated administration (Comer et al. 2001; Farré et al., 2004; Peiró et al., 2012). In one study, 
Farre et al. (2004) investigated the effects of two consecutive oral doses of MDMA (100 mg 
each) administered 24 hours apart.  The researchers found that the second dose produced further 
significant elevations in heart rate, blood pressure and ratings of euphoria compared to the first 
dose.  In contrast to these findings, tolerance appears to develop after repeated administration of 
methamphetamine.  For example, Comer et al. (2001) administered low oral doses (5-10 mg) of 
the drug twice daily for 3 consecutive days and reported that by day 2 some positive subjective 
effects were not significantly different from placebo. They also observed that more negative 
subjective effects (e.g., dizzy, bad drug effect) emerged following repeated administration of the 
drug. Of course, the apparent inconsistencies between the findings could be explained by the fact 





profiles.  For example, the half-life for MDMA is approximately 6 hours, whereas the half-life is 
about 12 hours for methamphetamine.  Another possibility is related to the dosing regimens 
employed; Farre and colleagues administered two MDMA doses (100 mg each) separated by 24 
hours, whereas Comer et al. (2001) gave methamphetamine (5, 10 mg) twice daily, at an 8-hour 
interval, for 3 consecutive days.  
In a more recent study of repeated MDMA administration, Peiró et al. (2012) gave two 
doses separated by 2 hours: the first was 50 mg and the second was 100 mg. Relative to the 
comparator condition (a single 100-mg dose), repeated MDMA administration significantly 
increased ratings of euphoria but disrupted performance (i.e., increased response time on a 
reaction time task). These findings indicate that the effects of an initial small dose of MDMA is 
enhanced by a larger dose administered a couple of hours later. While the study by Peiró and 
colleagues provided important information about repeated-dose administration of MDMA, it did 
not include conditions during which the same dose was administered repeatedly.  Another issue 
that was not addressed in the two earlier MDMA studies is whether residual effects emerge 
following repeated-dose administration, as was the case for methamphetamine. 
In an effort to address limitations in the existing literature, we undertook a double-blind, 
inpatient, within-participant study to evaluate the acute, repeated-dose and residual effects of oral 
MDMA administration (0, 50, and 100 mg) on several dependent variables, including 
cardiovascular, mood, and psychomotor performance effects. Placebo or MDMA was 
administered at three different time points within a 36-hour period to measure acute and 
repeated-dose effects. Following this period, placebo was administered over the next two days in 
order to assess residual effects. We hypothesized that: 1) repeated-dose administration would 





“negative” mood effects would emerge in the days following three consecutive drug 
administrations.  We made no predictions about MDMA-related effects on performance, because 
previous findings have been mixed. 
3.2 Methods and Materials 
3.2.1. Participants 
Twelve research volunteers (mean age was 28.9 ± 7.2 [± SD]) completed this 15-day 
inpatient study. Three participants were females (one Black and two Hispanic) and nine were 
males (three Black, three Hispanic, three White). Participants were recruited by word-of-mouth 
referrals, various online and newspaper advertisements in New York City newspapers and poster 
flyers. On average, volunteers had completed 13.0 ± 1.7 [(mean ± standard deviation (SD)] years 
of formal education.  Prior to study enrollment, participants passed comprehensive medical and 
psychiatric evaluations and were within normal weight ranges according to the Metropolitan Life 
Insurance Company height/weight table (body mass index: 24.4 ± 3.8).  All participants reported 
current MDMA use (1.28 ± 0.95 times/week).  Nine participants reported current cocaine use (1-
3 times/week), eleven reported current alcohol use (0.25-5 drinks/week) and marijuana use (1-7 
times/week), and five smoked five to 30 tobacco cigarettes/day.  No participant met criteria for 
an Axis I disorder and no one was seeking treatment for her/his drug use. 
Prior to study enrollment, each participant signed a consent form that was approved by 
the Institutional Review Board of the New York Psychiatric Institute (NYSPI); upon discharge, 
they were informed about experimental and drug conditions and were compensated at a rate of 
$35/day for their participation. They were also paid an additional bonus of $35/day for 






3.2.2. Pre-study training 
Prior to starting the study, participants completed two training sessions (3-4 hours per 
session) on computerized psychomotor tasks that would be used in the study in order to 
minimize the effects of learning on task performance. They were also familiarized with the 
residential laboratory and study procedures. On a separate day, participants received the largest 
single dose of MDMA (100 mg) to be tested inpatient in order to monitor any adverse reactions 
and provide them with experience with the study drug in the laboratory setting. Participants were 
not informed of the dose until study debriefing.  
3.2.3. Design  
Three groups of four participants lived in a residential laboratory located in the New 
York Psychiatric Institute for 15 days.  Table 1 shows that the study consisted of 3 five-day 
blocks of sessions, during which participants completed visual analog mood scales and 
psychomotor task batteries before and after MDMA administration.  Drug administrations 
occurred twice daily - 0900 and 2100 hours – and were counterbalanced across as well as within 
participant groups. On the first day of each block, only placebo was administered as this served 
as a baseline period. On the second day of each block, MDMA (0, 50, or 100 mg) was 
administered both in the morning and evening. On the third day of each block, placebo was 
administered at 0900 hours and MDMA was administered at 2100 hours, followed by two 
consecutive days of placebo administration at both dosing times. The three consecutive mornings 
of placebo administration were included in order to examine residual MDMA effects and as a 








Participants moved into the laboratory a day before the study began in order to further 
orient them to the laboratory and practice experimental procedures. Each day volunteers were 
awakened at 0800 hours.  After waking, participants completed a visual analog sleep 
questionnaire and baseline performance and subjective effects batteries beginning at 0815 hours.  
Subsequently, each participant was administered a capsule containing drug or placebo and 
weighed in a private vestibule. Then, they were given time to eat breakfast. Following breakfast, 
from 1000 to 1715 hours, participants engaged in work activities (i.e., completed various 
performance and subjective effects batteries) with an hour and a half lunch break (1300-1430 
hours), during which the social area was available.  In short, performance and subjective effects 
measures were assessed at baseline and 60, 110, 160, 210, 335, 375, 420, and 465 minutes after 
the first dose.  Cardiovascular measures and oral temperature were obtained at baseline and 25, 
50, 100, 150, 200, 250, 300, 325, 350, and 500 minutes post the first capsule administration.  
Subjective-effects ratings were also collected 150 minutes after the second dose and 
cardiovascular measures were assessed before and 25, 50, 100, and 150 minutes after the second 
capsule dosing. 
The social area was available to participants from 1715 to 2330 hours.  During this 
period, participants could interact with other study participants and engage in recreational 
activities such as playing video games or watching videotaped films. Two films were shown 
daily, beginning at 1900 and 2130 hours.  Social behavior was collected using a computerized 
observation program that prompted recording of each participant’s behavior every 2.5 minutes 
(e.g., Haney et al., 2007).  Behaviors were classified into private (time spent in 





area was further divided into time spent talking and time spent in silence.  Outcomes were total 
minutes spent engaging in each behavior per day.  At 2100 hours, participants received their 
second capsule.  Lights were turned out at 2400 hours for an 8-hour sleep period. Participants 
could smoke tobacco cigarettes and eat meals ad libitum from 0800 to 2330 hours.  
3.2.5 Subjective effects and psychomotor battery 
The computerized visual analog questionnaire consisted of 100-mm lines labeled “not at 
all” at one end and “extremely” at the other end (described in Hart et al., 2003).  The lines were 
labeled with adjectives describing a mood (e.g. “Anxious,” “Talkative,” “Unmotivated”), a drug 
effect (e.g. “Bad Drug Effect,” “Good Drug Effect,” “High”), or a physical symptom (e.g., 
“Headache,” “Muscle Pain,” “My heart is beating faster than usual”). Participants completed a 
drug-effect questionnaire (DEQ), during which they were required to rate “good effects” and 
“bad effects” on a five-point scale: 0 = “not at all” and 4 = “very much.”  Ratings of drug 
strength and desire to “take the drug again” were collected as well.  At 2240 hours, participants 
were asked to rate how “close [they feel] to those around me” and how much they “prefer to be 
alone” on 100-mm lines labeled “not at all” on one end and “extremely” on the other end. 
Computerized psychomotor tasks consisted of a 5 tasks: 1) the Digit-Symbol Substitution 
task (DSST; McLeod et al., 1982), designed to assess changes in visuospatial processing, 2) the 
Divided Attention Task (DAT), designed to assess changes in vigilance and inhibitory control 
(Miller et al., 1988); 3) the Digit Recall Task, designed to assess changes in immediate and 
delayed recall (Hart et al., 2001); 4) the Rapid Information Task (RIT), designed to assess 
changes in sustained concentration and inhibitory control (Wesnes and Warburton, 1983); and 5) 






3.2.6. Sleep monitoring 
Objective sleep was measured by tracking gross motor activity using the Actiwatch® 
Activity monitoring System (Actiwatch® ; Respironics Company, Bend, OR).  This system 
provided measures of total sleep time, sleep onset latency, sleep efficiency (total sleep time as a 
percentage of time in bed), and number of wake bouts (Kushida et al., 2001).  Subjective sleep 
experience from the immediately preceding sleep period was measured by a visual analog sleep 
questionnaire each morning. This questionnaire consisted of a series of 100-mm lines labeled 
"not at all" at one end and "extremely" at the other end.  The lines were labeled: "I slept well last 
night," "I woke up early this morning," "I fell asleep easily last night," "I feel clear-headed this 
morning," "I woke up often last night," "I am satisfied with my sleep last night," and a fill-in 
question in which participants were asked to estimate the number of hours they thought they 
slept the previous night (Haney et al. 2001). 
3.2.7 Drug 
Placebo and two active MDMA doses (50 and 100 mg) were tested. MDMA 
hydrochloride was provided by Dr. David Nichols of Purdue University and packaged by the 
Pharmacy Department of the New York State Psychiatric Institute. The appropriate amount of 
MDMA hydrochloride was placed into a white #00 opaque capsule along with lactose filler. 
Placebo consisted of white #00 capsules containing only lactose.  
3.2.8 Data Analysis  
Acute cardiovascular activity, subjective effects and psychomotor performance were 
analyzed using two-factor repeated-measures analyses of variance (ANOVAs): the first factor 
was drug condition (placebo, 50, and 100 mg MDMA), and the second factor was time (time and 





assessed at time points baseline, 25, 50, 100, 150, 200, 250, and 300 minutes post drug 
administration). Repeated-dose and residual effects analyses included an additional third factor 
of day.  Repeated-dose effects were assessed by comparing peak effects produced by the first 
drug administration within each dosing to the third drug administration. The residual effects of 
repeated drug administration was examined using planned contrasts that compared performance 
and mood upon awakening the first placebo day following active drug administration to the 
corresponding first placebo day following the period of placebo administration. Sleep and 
cigarette intake data were analyzed using a two-factor ANOVA: the first factor was drug 
condition and the second factor was day.  For all analyses, ANOVAs provided the error terms 
needed to calculate the following planned comparisons: acute and residual 1) placebo vs. active 
doses and 2) 50 vs. 100 mg MDMA; repeated dose 1) 50 mg: (first versus third administration) 
and 2) 100 mg: (first versus third administration).  p Values were considered statistically 
significant at less than 0.05, using Huynh-Feldt corrections when appropriate.  
3.3 Results 
3.3.1 Cardiovascular and oral temperature effects 
Acute effects 
Figure 3.1 shows that MDMA increased heart rate over time.  Active doses produced 
significant increases in heart rate and blood pressure compared to placebo (p < 0.01).  The 100-
mg dose produced significantly larger increases in systolic and diastolic blood pressure than the 
50 mg dose (p < 0.05).  There were no significant drug effects on oral temperature.  
Repeated-dose effects 
The only cardiovascular measure that varied significantly as a function of repeated-





above placebo (see Figure 3.2).  Under the 50-mg condition, peak heart rate was 100.75 bpm 
following the first administration but only 90.67 bpm following the third administration (p < 
0.02). Under the 100-mg condition, heart rate peaked at 105.67 bpm following the first drug 
administration but was down to 89.67 after the third administration (p < 0.001).  Following the 
third administration, active drug conditions significantly increased systolic and diastolic blood 
pressure relative to placebo (p < .001).  No other significant cardiovascular effects were 
observed. 
Residual effects 
There were no significant residual cardiovascular effects. 
3.3.2 Subjective effects 
Acute effects 
Figure 3.1 shows the effects of MDMA on selected subjective-effect ratings over time. 
Peak effects for both doses were observed 1 hour after ingestion. Relative to placebo, MDMA 
(50 and 100 mg) significantly increased ratings of “good drug effect” and “stimulated” (p < 
0.0001), and the larger dose produced greater increases than the smaller dose (p < 0.001).  In 
addition, while both active doses produced significantly larger increases on ratings of “sedated” 
compared to placebo (p < 0.05), only the 100-mg dose significantly increased ratings of “jittery” 
(p < 0.001 for all comparisons).  On the DEQ, both MDMA doses increased ratings of “good 
effect” and “drug strength” compared to placebo (p = 0.001); the 100-mg dose produced greater 
increases on these measures than the 50-mg dose (p < 0.05).  Table 3.2 summarizes other 
significant acute effects observed on the visual analog questionnaire and the DEQ. In general, 







Figure 3.2 shows the repeated-dose effects of MDMA on selected subjective-effect 
ratings.  Rating of “good drug effect” and “jittery” were attenuated with repeated drug 
administration, though still remained significantly elevated relative to placebo. Under the 100-
mg condition, both ratings were significantly decreased following the third administration 
compared to the first administration (p < 0.05).  Following the third dosing, active drug 
conditions significantly increased ratings of “good drug effect” and  “stimulated” compared to 
placebo,  (p = 0.001).  Only the larger dose increased ratings of “sedated” and “jittery” (p < 
0.05).  Following the second administration (Day 2), ratings of “I feel close to those around me” 
were significantly increased by both MDMA doses compared to placebo (p < 0.05).  Following 
the third administration (Day 3), closeness ratings remained significantly increased by the larger 
MDMA dose compared to placebo (p < 0.05).   Relative to placebo, both doses of MDMA 
significantly decreased ratings of “I would prefer to be alone” after the third dosing (p < 0.01).  
Other significant VAS and DEQ effects following repeated-dosing are summarized in Tables 3.3 
and 3.4. 
Residual effects 
No significant residual subjective effects were noted. 
3.3.3 Psychomotor performance effects 
Acute effects 
There were no significant acute drug effects on psychomotor performance. 
Residual effects 







3.3.4 Sleep effects 
 
Figure 3.3 illustrates the effects of MDMA administration on objective and subjective 
sleep measures during the sleep period that began 3 hours after the second drug administration 
(Day 2).  During this period, the larger MDMA dose decreased both the objective and subjective 
number of hours participants slept relative to placebo (p < 0.05).  While both MDMA doses 
decreased participants’ ratings of “fell asleep easily” compared to placebo (p < 0.05), only the 
larger MDMA dose increased objective measures of sleep onset latency (p < 0.01 for all 
comparisons). Under both active drug conditions, subjective ratings of “fell asleep easily” were 
significantly increased on Day 3 compared to Day 2 (p = 0.001).  No other significant sleep 
effects were observed. 
3.3.5 Effects on cigarette smoking 
For the six participants who smoked cigarettes during the study, both MDMA doses 
increased the number of cigarettes smoked compared to placebo on Day 2 (p < .05).  The average 
increase was approximately four to five cigarettes (15.7±2.7 [50 mg] and 15.3±2.8 [100 mg], vs. 
10.8±2.2 [placebo]).  No other significant effects on cigarette intake were observed. 
3.3.6 Effects on social interactions 
Only the larger MDMA dose increased the amount of time participants engaged in verbal 
conversation in the social area compared to placebo following the third administration (Day 3) (P 













3.4 Discussion  
 
The current findings show that repeated-dosing administration of MDMA produced 
mixed cardiovascular and subjective effects. Blood pressure was significantly increased after 
each of the three successive MDMA administrations, but heart rate increases were no longer 
significant by the third administration.  Subjective-effect ratings following repeated dosing were 
also complex.  Both positive (e.g., “good drug effect”) and negative (e.g., “jittery”) ratings were 
significantly elevated across all drug dosings.  However, even though ratings were significantly 
increased compared to placebo, elevations produced by the larger MDMA dose were markedly 
smaller after the third administration compared to the first, indicating partial tolerance. In 
general, these data replicate previous results from investigations assessing acute MDMA-related 
effects (e.g., Camí et al., 2000; Kirkpatrick et al., 2012); they extend such findings by 
demonstrating attenuation of some effects following repeated MDMA administration.  
The current result showing that repeated MDMA dosing produced tolerance to heart rate 
elevations and the finding that repeated drug administration did not produce additive blood 
pressure effects were unexpected. Anecdotally, MDMA is sometimes used in multiple doses 
within a short period, which has raised concerns about potential dangerous additive 
cardiovascular effects. Previously, researchers investigated this issue and reported data consistent 
with this concern. In the first study, Farré and colleagues (2004) administered two 100-mg 
MDMA doses separated by 24 hours and assessed multiple measures, including cardiovascular 
effects. They found that the second MDMA administration produced significantly larger 
increases in heart rate and blood pressure than did the first. In another study, Peiró et al. (2012) 
assessed MDMA repeated-dose effects by administering a smaller dose (50 mg) followed 2 





researchers also reported significant cardiovascular elevations under the two active drug 
conditions. One potential reason for the apparent inconsistent findings between the present data 
and previous results is related to the different study designs. The current study assessed MDMA-
related repeated effects following three drug administrations at 12- and 24- hour intervals, 
respectively, whereas previous investigations of MDMA repeated effects only included 2 
administrations at 24- and 2- hour intervals, respectively (Farré et al., 2004; Peiró et al., 2012).  
It is important to also note that while the studies by Farré et al. (2004) and Peiró et al. (2012) 
found additive cardiovascular activity, these effects were small and unlikely to prompt clinical 
concerns. 
Our results indicate a diminution but not absence of positive and negative subjective 
effects with repeated dosing. Despite some evidence for partial tolerance, it should be noted that 
participants still reported substantial amounts of euphoria after the third MDMA dose relative to 
placebo.  Previous research examining two MDMA administrations did not demonstrate any 
attenuation of subjective effects (Farré et al. 2004; Peiró et al. (2012).  However, when another 
amphetamine—methamphetamine (5, 10 mg)—was assessed using a 3-dose study design similar 
to the current study, tolerance to some positive effects was observed (Comer et al., 2001).  
Comer and colleagues (2001) reported a significant diminution of “good drug effect” and “high” 
by the third methamphetamine administration compared the first administration.  Decreased 
negative mood effects (e.g., “jittery”) were also observed with repeated dosing in the current 
study.  This is an important finding because negative mood effects can sometimes decrease drug 
intake.  Future studies should investigate this issue by measuring actual drug intake and variation 





The current study also sought to expand upon the limited database documenting residual 
mood effects of MDMA administration.  Anecdotal reports indicate the emergence of a short-
term depressive state in the days after MDMA use, a phenomenon colloquially referred to as 
“Suicide Tuesday” (e.g., Parrott and Lasky, 1998).  Accordingly, we hypothesized that negative 
subjective effects would emerge in the days following three successive drug administrations.  
The current data do not lend support for the hypothesis, as negative mood ratings (i.e., 
“depressed,” “miserable,” and “anxious”) were not significantly altered 12- to 48- hours after the 
third MDMA dosing.  Multiple factors could potentially account for the apparent discrepant 
laboratory data and anecdotal observations. In the natural ecology, individuals frequently take 
multiple drugs (e.g., alcohol and other sedatives) and may not get sufficient amounts of sleep 
following an evening of drug use.  In the current study, only one drug was tested (MDMA),  and 
each evening lights were turned out for a required 8-hour sleep period.   
Objective and subjective measures of sleep were disrupted by the larger MDMA dose 
administered three hours before the sleep period (Day 2).  Specifically, participants slept 
approximately two fewer hours and reported great difficulties falling asleep when the 100-mg 
MDMA dose was administered compared to placebo. Under the 50-mg dose condition, the only 
effect observed on sleep was that participants’ reported greater difficulties falling asleep. In 
general, these findings are in agreement with data from a previous investigation evaluating 
MDMA-related sleep effects (Randall et al., 2009).  Randall and colleagues (2009) administered 
a single MDMA dose (2 mg/kg) five hours prior to bedtime.  They showed that the drug 
increased sleep latency and decreased total sleep time without producing next-day sleepiness. 





In conclusion, the current findings show that cardiovascular effects following repeated 
MDMA administrations diminished (heart rate) or remained the same (blood pressure). These 
findings are important because of anecdotal concerns about dangerous additive cardiovascular 
effects after multiple doses of the drug administered within a relatively short time frame. We 
found no evidence supporting such concerns. Another important finding was that negative mood 
following repeated MDMA dosing was unaltered. The drug produced few residual effects, even 
after repeated dosing.  Future studies assessing the repeated-dosing effects of MDMA should 





















Chapter 4: General Discussion 
 
Concern about illicit use and abuse of amphetamines has increased dramatically over the 
past decade.  Yet, much of our knowledge about amphetamine-related effects in humans is 
anecdotal.  The current studies addressed two gaps in our knowledge relating to effects of these 
drugs in humans: 1) the overlapping and divergent effects of d-amphetamine and 
methamphetamine, and 2) MDMA-related repeated-dose and residual effects. 
4.1 d-amphetamine and methamphetamine 
 
 Although d-amphetamine and methamphetamine are commonly regarded as distinct in 
the U.S., there are few empirical studies that directly compare the effects of these drugs in 
humans.  Study 1 addresses this issue by comparing the effects of the amphetamines on well-
validated measures of regulatory focus and task engagement.  Data from this study showed that 
d-amphetamine and methamphetamine produce nearly identical effects: both drugs increased 
both “prevention” focus and enhanced engagement on a task assessing vigilance, suggesting a 
regulatory “fit.”  In general, these results are consistent with previous data from investigations on 
the subjective effects of d-amphetamine and methamphetamine (Kirkpatrick et al., 2011; Martin 
et al., 1971; Sevak et al., 2009). These data are the first to demonstrate that intranasal d-
amphetamine and methamphetamine produce nearly identical stimulant effects on more sensitive 
psychological measures of regulatory focus and engagement.   
It is clear from findings from early and current research that d-amphetamine and 
methamphetamine produce a similar profile of prototypical stimulant effects.  This empirical 
evidence suggests that the drugs are essentially the same, which is consistent with the way in 
which amphetamines were viewed for most of the twentieth century.  The drugs were used 





and considered panaceas.  Despite the fact that the amphetamines were perceived as similar for 
over four decades, the general public currently views d-amphetamine and methamphetamine as 
markedly different. For example, d-amphetamine is considered a safe and effective therapeutic 
for the treatment of ADHD; in 2012, Adderall (e.g., d-amphetamine) was ranked 70 out of 200 of 
the most widely prescribed medications (Bartholow, 2012).  In contrast, methamphetamine is 
perceived as a more potent, addictive drug and is rarely prescribed as an ADHD medication 
(Bartholow, 2012).  
As in the past, considerable national concern regarding the purported deleterious effects of 
methamphetamine abuse has encouraged lawmakers to pass restrictive legislation.  In 2005, the 
U.S. federal government passed the Combat Methamphetamine Epidemic Act which requires 
identification and a signature for sales of over-the-counter medications containing ingredients 
that are involved in the illicit synthesis of methamphetamine (e.g., pseudoephedrine and 
ephedrine). It is important to note, however, that data from early and current empirical studies 
are inconsistent with recent public concerns and legislation relating to methamphetamine. 
4.2 3,4-methylenedioxymethamphetamine 
 An important gap addressed by the current study was the lack of information about the 
repeated-dose and residual effects of MDMA.  The major scientific contribution of the current 
study is that it was the first investigation of the cardiovascular, subjective and performance 
effects of repeated administration of a wide range of MDMA doses (0, 50, 100 mg).  Following 
repeated dosing, heart rate elevations were no longer statistically significant and blood pressure 
increases remained the same.  Subjective-effect ratings remained significantly increased, but 
such increases were diminished relative to acute drug effects. Measures of sleep were decreased 





or residual effects were observed. 
These findings provide important public health information regarding the consequences 
of MDMA use.  Users of illicit MDMA reportedly administer multiple doses of the drug within a 
relatively short time frame, which has sparked concerns about dangerous additive cardiovascular 
effects.  However, data from the present study do not support anecdotal reports of toxic effects 
associated with this common recreational MDMA use pattern.  Furthermore, the finding that 
MDMA produced no residual mood effects is important given popular reports about depressive 
states in the days following repeated dosing.   
While there is a plethora of research on amphetamine- and methamphetamine-related 
effects, the database documenting MDMA-related effects is limited.  Questions still remain about 
the effects of this amphetamine derivative in humans.  For example, it is possible that additive 
cardiovascular and negative mood effects may emerge following multiple dosing of MDMA at 
shorter intervals. Future studies on MDMA-related repeated-dosing effects are needed and 
should decrease the dosing interval.  
4.3 Concluding Remarks 
As in the past, findings from empirical research are inconsistent with conventional 
perceptions of amphetamines in today’s society. The present results indicate that d-amphetamine 
and methamphetamine produce a similar profile of effects.  Yet, d-amphetamine and 
methamphetamine are viewed as distinct drugs.  Data from study 2 show no dangerous additive 
cardiovascular or residual effects of MDMA.  Abuse of this drug, however, is commonly 
associated with deleterious cardiovascular and mood effects.  As a result of public concern, 
methamphetamine is often ignored as an effective medication and MDMA remains categorized 





History relating to amphetamines appears to be repeating itself.   Since the early twentieth 
century, empirical evidence indicates that amphetamines are nearly identical drugs.  However, 
the best available scientific data are often ignored in the face of sensational media claims about 
the dangerous effects associated with abuse of a particular amphetamine.   Informed by anecdotal 
reports, lawmakers pass legislation distinguishing various amphetamines.  In the future, it is 
likely that similar statements will be made in the popular press about an unfamiliar “new” type of 
amphetamine and, in turn, legislation will hastily be passed.  However, the present thesis aims to 
highlight the importance of a critical examination of available early and current empirical 
evidence on the effects of amphetamines in humans.  This scientific approach will hopefully 
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Table 1.1 Early medical uses of amphetamines 
Medical Use  
1. Narcolepsy 
2. Epilepsy 




7. Barbiturate Intoxication and Narcosis 
8. Avertin Anesthesia 
9. Morphine Addiction 
10. Codeine Addiction 
11. Caffeine Mania 
12. Nicotinism 
13. Disseminated Sclerosis 
14. Myathenia Gravis 
15. Myotonia 
16. Electric Convulsion Therapy 
17. Head Injuries 
18. Infantile Cerebral Palsy 
19. Problem Children and Enuresis 
20. Migraine 
21. Urticaria 
22. Meniere’s Syndrome 
23. Sea Sickness 
24. Persistent Hiccup 
25. Dysmenorrhoea 
26. Ureteral Colic 
27. Obesity 
28. The Irritable Colon 
29. X-Ray Visualization 
30. Irradiation Sickness 
31. “Restless Legs” 
32. Carotid Sinus Syndrome 
33. Hypotension 




38. Night Blindness 
39. Libido 













Table 1.2 Summary of controlled substance schedules 
Schedule  Criteria Examples 
Schedule I a. High potential for abuse 
b. No currently acceptable medical use in treatment in the U.S. 





Schedule II a. High potential for abuse 
b. Currently accepted medical use 






Schedule III a. Potential for abuse less than I and II 
b. Currently accepted medical use 






Schedule IV a. Low potential for abuse relative to III 
b. Currently accepted medical use 
c. Abuse may lead to limited physical dependence or 









Figure 1.1 The effects of subcutaneous and oral amphetamine on cardiovascular measures in 








Figure 1.2 Benzedrine inhalers sold over-the-counter. 
 
Figure 1.3 A Smith, Klein and French advertisement for Benzedrine Sulfate (e.g., amphetamine) 








Figure 1.4 Smith, Klein and French advertisements for military use of Benzedrine inhaler in the 







































Table 2.1 Study design 
Week Drug Monday Tuesday Wednesday Thursday Friday 
1 MA (mg/70 kg) (50)   (12)  
2 AMPH (mg/70kg) (12)   (50)  
3  (0)     
 
Table 2.2 d-amphetamine- and methamphetamine-related effects on task engagement ratings 
 Placebo 12 mg AMPH 12 mg MA 50 mg AMPH 50 mg MA 
Measure Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) Mean (SEM) 
 
Task engagement ratings (max = 9) 
“Felt bad during task” 2.07 (0.47) *1.54 (0.10) *1.54 (0.10) *1.07 (0.07) *1.0 (0.00) 
“Felt good during task” 5.85 (0.56) 6.30 (0.62) *7.50 (0.40) *7.0 (0.50) *7.10 (0.50) 
“Felt happy during 
task” 
5.46 (0.31) 6.07 (0.33) *6.50 (0.05) *6.70 (0.44) *6.7 (0.43) 
 
* p < .05, significantly different from placebo. VAS: visual analog scale. DEQ: drug-effect 




































































































































Table 3.1 Study Design 
Time Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 
0900 P MDMA1 P P P P MDMA2 P P P 
2100 P MDMA1 MDMA1 P P P MDMA2 MDMA2 P P 
           




15      
0900 P P P P P      
0900 P P P P P      
 
Table 3.2 Acute (Administration 1) MDMA-related effects on subjective-effect ratings 
 Placebo       50 mg MDMA        100 mg MDMA 
Measure Mean (SEM) Mean (SEM) F Value Mean  (SEM) F Value 
 
VAS ratings (max = 100) 
Anxious 1.92 (1.66) 18.58 (9.82) 7.13 25.67 (10.30) *14.47 
Blurred vision 3.83 (3.66) 16.58 (7.94) 88.84 42.50 (10.13) *§36.50 
Can’t concentrate 20.08 (6.86) 41.50 (11.01) *8.12 45.58 (10.56) *11.51 
Chills 10.70 (7.31) 33.80 (11.40) *11.93 50.50 (12.41) *§35.28 
Confused 1.67 (1.67) 17.50 (8.87) *7.57 17.75 (7.0) *7.81 
Content 58.83 (9.07) 66.74 (9.22) 0.89 79.92 (7.53) *6.33 
Dizzy 4.83 (3.60) 18.33 (9.60) *9.01 22.67 (9.41) *15.72 
Friendly 55.50 (6.69) 70.50  (5.05) *15.19 79.42 (6.86) *2.21 
Heart pounding 6.33 (5.10) 32.41 (12.02) *17.96 39.08 (12.81) *28.32 
High 8.33 (4.10) 61.83 (11.65) *63.24 85.83 (6.78) *§132.71 
Noises seem loud 7.08 (5.80) 23.33 (10.11) *8.79 42.33 (12.45) *§41.36 
Restless 10.58 (5.57) 20.67 (7.88) 2.06 31.58 (10.85) *8.96 
Social 57.58 (5.52) 64.67 (7.90) 1.02 72.92 (9.0) *4.76 
Stimulated 5.583 (3.05) 55.75 (12.93) *48.04 86.25 (6.56) *§124.21 
Sweating 0.25 (0.25) 9.50 (6.48) 2.49 30.08 (12.62) *§25.89 
Talkative 45.25 (6.16) 55.42 (7.67) 1.79 67.58 (11.77) *8.62  
 
DEQ ratings  
Bad drug effect 0.08 (0.08) 0.33 (0.14) *3.04  0.75  (0.37) *§21.63 
Desire to take again 1.17 (0.47) 2.75 (0.31) *13.25  3.42  (0.29) *39.97 
Like drug 0.33 (0.59) 2.58 (0.21) *32.93  3.25  (0.38) *61.84 
 
* p < .05, significantly different from placebo. § p < .05, significantly different from 50 mg 
MDMA. VAS: visual analog scale. DEQ: drug-effect questionnaire. SEM: standard error of the 
mean 









Table 3.3 MDMA-related effects on subjective-effect ratings (Administration 3) 
 Placebo       50 mg MDMA        100 mg MDMA 
Measure Mean (SEM) Mean (SEM) F Value Mean  (SEM) F Value 
 
VAS ratings (max = 100) 
Heart pounding 1.83 (1.83) 31.17 (9.13) *39.95 32.83 (11.45) *44.62 
High 7.25 (3.87) 47.25 (8.76) *71.52 65.58 (8.75) *§152.12 
Noises seem loud 10.33 (6.31) 19.75 (9.72) *5.65 26.17 (9.50) *15.96 
 
DEQ ratings (max = 4) 
Drug strength 0.50 (0.20) 2.25 (0.13) *66.38 2.33 (0.40) *72.85 
Desire to take again 1.33 (0.51) 2.08 (0.33) *2.97 2.83 (0.41) *11.89 
Good drug effect 0.42 (0.19) 2.25 (0.25) *49.67 2.42 (0.43) *59.11 
Like drug 0.17 (0.56) 1.92 (0.42) *19.92 2.17 (0.71) *26.02 
 
* p < .05, significantly different from placebo. § p < .05, significantly different from 50 mg 
MDMA. 
 
Table 3.4 Repeated-dose effects on subjective ratings 
 
VAS ratings (max = 100) 
Anxious 13.67 (7.62) 16.92 (9.92) 0.33 24.75 (9.14) 10.92 (6.22) *5.92 
Heart pounding 30.67 (9.61) 31.17 (9.13) 0.01 43.50 (11.17) 32.83 (11.45) †5.28 
Noises seem loud 16.58 (8.60) 19.75 (9.72) 0.64 39.75 (11.24) 26.17 (9.47) * 11.75 
 
DEQ ratings (max = 4)  
Drug strength 2.58 (0.15) 2.25 (0.13) 2.41 3.58 (0.19) 2.33 (0.40) *33.87 
Good drug effect 2.75 (0.25) 2.25 (0.25) 3.69 3.42 (0.19) 2.42 (0.43) *14.78 
Like drug 2.58 (0.19) 1.92 (0.42) 2.90 3.25 (0.25) 2.17 (0.71) *7.63 
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Figure 3.1. Selected acute (administration 1) cardiovascular and subjective-effect ratings as a 
function of drug dose and time.  Error bars represent 1 SEM.  Overlapping error bars were 
omitted for clarity.  
 
 
Figure 3.2 Selected repeated dose cardiovascular and subjective-effects ratings as a function of 
drug condition and administration.  Error bars represent 1 SEM.  Overlapping error bars were 
omitted for clarity. Admin. 1= administration 1. Admin 3= administration 3.  
 
 
Figure 3.3 Sleep measures on Day 2 (i.e., sleep period that began 3 hours after the second drug 
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